Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|September 19, 2018
Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic SyndromesCarolien Duetz, Theresia M Westers, Arjan A van de Loosdrecht
Current Opinion in Oncology|December 27, 2019
Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?Carolien Duetz, Costa Bachas, Theresia M Westers, et al.
Leukemia|March 8, 2024
Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cellsMargot F van Spronsen, Sofie Van Gassen, Carolien Duetz, et al.
Cytometry. Part B, Clinical Cytometry|December 21, 2021
The flow cytometry myeloid progenitor count: A reproducible parameter for diagnosis and prognosis of myelodysplastic syndromesUlrika Johansson, Neil McIver-Brown, Matthew Cullen, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|May 4, 2021
Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromesCarolien Duetz, Sofie Van Gassen, Theresia M Westers, et al.
British Journal of Haematology|October 11, 2021
The wider perspective: twenty years of clinical trials in myelodysplastic syndromesCarolien Duetz, David G J Cucchi, Tobias B Polak, et al.
Cytometry. Part B, Clinical Cytometry|March 15, 2022
Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometryCosta Bachas, Carolien Duetz, Margot F van Spronsen, et al.
British Journal of Haematology|March 25, 2021
Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtypeCarolien Duetz, Theresia M Westers, Florentien E M In 't Hout, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple MyelomaChristie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Pageof 2